OCT. 24 - 28
The Galien Week of Innovation presents an exclusive series of thematic webinars featuring nominees of the Prix Galien USA Awards discussing the topics on everyone’s minds through the lens of the life-changing innovations they have successfully brought to market.
SEE THE NOMINEES
CATEGORY
Medtech
Monday Oct. 24
11 AM - 2 PM ET
-
Program & Registration
-
Intro
WEBINAR
FORMAT
12 PM - 1 PM ET I Medical Devices and Implants – Cardiovascular and Cancer
How are systems design, electronics and engineering making invasive, high-risk surgical procedures a thing of the past for these two major killers?
1 PM - 2 PM ET I Medical Devices and Implants - Other Therapeutic Areas
What is Med Tech innovation doing for patients with specialized needs for treatment?
To mark the Prix Galien USA’s upcoming October 24-28 “Week of Biomedical Innovation,” distinguished members of the USA Prix Galien Awards Committee will chair three webinars highlighting each of the 25 nominated products they have selected for the best Med Tech category.
These virtual expert panelist exchanges will offer the opportunity for webinar participants to assess the current state of innovation in Med Tech, covering key aspects of clinical progress and differentiation; the ways patient care is now being conducted outside traditional delivery settings; and the next wave of promising breakthrough device and diagnostic technologies, including their transformative – and potentially disruptive – effect on health care productivity and outcomes worldwide.Sessions will be chaired by a member of the Prix Galien USA Committee and will include a representative of the research team for each nominee product.
CATEGORY
Digital Health
Monday Oct. 24
2 PM - 4 PM ET
-
Program & Registration
-
Intro
WEBINAR
FORMAT
2 PM - 3 PM ET I Disease Management
In what ways can these new technologies contribute to the realization of better outcomes for patients at less cost to overburdened health systems?
3 PM - 4 PM ET I Clinical Trial Management and Wellness Care
Are researchers, physicians and regulators ready to embrace advanced, low-touch approaches to streamline the cumbersome infrastructure of clinical trials? And are insurers and health systems prepared to reward software-driven patient self-care technologies, particularly by recognizing prevention and wellness as an integral element of service provision?
Fed by the demand for remote technology applications in the midst of an unprecedented global pandemic, digital health is having its moment. Evidence suggests that digital applications in disease management and personalized care and wellness solutions can lead to significant gains in the productivity of health services. Among the benefits are a lowering of the cost of care, improvements in individual patient outcomes and helping regulation and clinical protocols become more targeted and efficient. The economic payoff is equally impressive – worldwide, the digital health industry is forecast to generate more than $800bn in revenue through the end of this decade. In many ways, the advent of personalized medicine would be impossible without digital health products – a rate of progress exemplified by the 13 software-based devices and apps nominated for this year’s Prix Galien for best innovation in the digital space. The sessions will be chaired by a member of the Prix Galien Digital Health Committee and will include a representative of the research team for each nominee product.
CATEGORY
Biotech
Tuesday Oct. 25
11 AM - 2 PM ET
-
Program & Registration
-
Intro
WEBINAR
FORMAT
11 AM - 12 PM ET I Rare Diseases
What is the underlying science behind clinical progress in therapies that promise a genetics-based cure for devastating rare diseases and how will this contribute to the next wave of innovations? What are the implications for continued patient access to these high-cost, high-touch treatments – does the ROI calculation for rare diseases still add up?
12 PM- 1 PM ET I Cancer
Can the foundational biologic understandings now being brought to cancer care be leveraged to secure a targeted, more personalized approach to treatment, particularly in solid tumors?
1 PM - 2 PM ET I Chronic/Autoimmune Disorders and Vaccines
Given that many chronic diseases have an infectious origin, what learnings can be had by the most recent innovations in vaccine development technology in raising the bar on innovations to address the huge unmet need against conditions that kill millions?
To mark the Prix Galien USA’s upcoming October 24-28 “Week of Innovation,” distinguished members of the Prix Galien USA Awards Committee will chair three webinars highlighting each of the 21 nominated products they have selected for the best Biotechnology category. These virtual expert panelist exchanges will offer the opportunity for webinar participants to assess the current state of innovation in Biotechnology, covering key aspects of clinical progress and differentiation; the ways patient care is now being conducted outside traditional delivery settings; and the next wave of promising medicines, vaccines and diagnostics technologies, including their transformative – and potentially disruptive – effects on health care productivity and outcomes worldwide.
The sessions will be chaired by a member of the Prix Galien USA Committee and will include a representative of the research team for each nominee product.
CATEGORY
Incubator / Accelerator / Equity
Tuesday, Oct. 25
2 PM - 4:30 PM ET
-
Program & Registration
-
Intro
WEBINAR
FORMAT
2 PM - 3:30 PM ET I Disease Management
Incubators and accelerators are pivotal in developing innovative solutions to address humanity’s most pressing health challenges. Why are academic institutions, major medical centers, and significant life science companies launching incubators and accelerators to offer guidance to biotech, digital health, health information, and medical device start-ups? Beyond financial resources, how are these groups working to advance ideas into the marketplace, and what is their impact?
3:30 PM - 4:30 PM ET I Clinical Trial Management and Wellness Care
An innovator’s connection to a leadership accelerator, incubator or private equity organization is a strong indicator of success. Financial support is part of the commitment, as are experience and connections. How do these investment and counseling groups help start-ups with their clinical trial design, navigate regulatory and payer system complexities or build a go-to marketing plan? Beyond access to cash, what makes the innovator’s connection to an accelerator, incubator or private equity group success critical?
The sessions will be chaired by a member of the Prix Galien USA Committee and will include a representative of the research team for each nominee product.
CATEGORY
Pharma
Wednesday, Oct. 26
11 AM - 2 PM ET
-
Program & Registration
-
Intro
WEBINAR
FORMAT
11 AM - 12 PM ET I Hematologic Cancers and Gene-based “Tumor Agnostic” Therapies
How much more mileage is in store for blood-based cancer survival rates, which have been increasing steadily in recent years? And what is being done about the flip side of this success, expressed in more treatment-related morbidities, disease relapse and higher incidence of other malignancies?
12 PM - 1 PM ET I Solid Tumor Cancers
What is the state of progress in extending cell-based gene therapies to fight solid tumor cancers? How successful has the pharma industry been in building new therapeutic and diagnostic platforms to fight major cancers and address their prevalence in vulnerable populations, including the aged, minorities, and pediatric patients?
1 PM- 2 PM ET I Chronic and Autoimmune Disorders
Chronic non-communicable diseases now account for three quarters of annual deaths worldwide, with a fast rising percentage taking place in low and middle income countries. With this in mind, how important is incentivizing more industry investment in costly clinical trials and other research targeting key areas of unmet need in major chronic conditions like CVD? Will a better understanding of the common molecular signatures that underlie many serious autoimmune disorders result in more progress in therapeutic interventions, including prevention?
2 PM - 3 PM ET I Rare Genetic Diseases
Will progress in therapies that promise a genetic cure for devastating rare diseases lead to similar innovations in patient access to these high-cost, high-touch treatments?
3 PM - 4 PM ET I Anti-Viral Drugs and Women’s Health
With a global pandemic raising awareness of the importance of vaccines and anti-viral/anti-microbial drugs, are private-sector R&D incentives aligned to meet future contagion threats?
To mark the Prix Galien USA’s upcoming October 24-28 “Week of Innovation,” distinguished members of the Prix Galien USA Awards Committee will chair five webinars highlighting each of the 32 nominated products they have selected in the best pharmaceutical agent category. These virtual expert panelist exchanges will offer the opportunity for webinar participants to assess the current state of innovation in branded pharmaceuticals, covering key aspects of clinical progress and differentiation; the ways patient care is being conducted outside traditional delivery settings; and the next wave of promising medicines, vaccines and diagnostic technologies, including their transformative – and potentially disruptive – effects on health care productivity and outcomes worldwide. The sessions will be chaired by a member of the Prix Galien USA Committee and will include a representative of the research team for each nominee product.
Galien Jubilee Forum
Thursday Oct. 27
7:30 AM - 4:15 PM ET
Alexandria Center for Life Sciences
New York City
Prix Galien Awards
Thursday Oct. 27
6:30 PM - 10:30 PM ET
Museum of Natural History
New York City
